Use of Raltegravir in Pediatric HIV-1 Infection

Marcia L. Buck, Pharm.D., FCCP, FPPAG; Kristi N. Hofer, Pharm.D; Michelle W. McCarthy, Pharm.D.; FASHP Susan B. Cogut, Pharm.D

Disclosures

Pediatr Pharm. 2012;18(1) 

In This Article

Dosing Recommendations

The recommended dose of raltegravir in adults and adolescents 12 years of age and older is 400 mg given twice daily. In children 6 to 12 years of age weighing at least 25 kg, either the adult dose or weight-based dosing may be used as described in the table below. If the child weighs less than 25 kg, or in children 2 to 6 years of age, weight-based dosing should be used, to a maximum of 300 mg twice daily.[3] No dosage adjustment is needed for patients with renal impairment or mild to moderate hepatic impairment.[13] The administration of raltegravir to patients with severe hepatic impairment has not been studied.

Raltegravir can be given with or without food. The film-coated tablets must be swallowed whole, while the chewable tablets may be chewed, crushed, or swallowed whole. The two tablet formulations are not bioequivalent, and therefore are not interchangeable.[2,3]

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....